JP2020536893A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536893A5 JP2020536893A5 JP2020520115A JP2020520115A JP2020536893A5 JP 2020536893 A5 JP2020536893 A5 JP 2020536893A5 JP 2020520115 A JP2020520115 A JP 2020520115A JP 2020520115 A JP2020520115 A JP 2020520115A JP 2020536893 A5 JP2020536893 A5 JP 2020536893A5
- Authority
- JP
- Japan
- Prior art keywords
- ppm
- free base
- base hydrate
- crystal form
- resonance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012458 free base Substances 0.000 claims 10
- 239000013078 crystal Substances 0.000 claims 9
- IIXWYSCJSQVBQM-LLVKDONJSA-N lorlatinib Chemical compound N=1N(C)C(C#N)=C2C=1CN(C)C(=O)C1=CC=C(F)C=C1[C@@H](C)OC1=CC2=CN=C1N IIXWYSCJSQVBQM-LLVKDONJSA-N 0.000 claims 9
- 229950001290 lorlatinib Drugs 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 238000001228 spectrum Methods 0.000 claims 7
- 238000004922 13C solid-state nuclear magnetic resonance spectroscopy Methods 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 238000004319 19F solid-state nuclear magnetic resonance spectroscopy Methods 0.000 claims 3
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims 3
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000001144 powder X-ray diffraction data Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762570326P | 2017-10-10 | 2017-10-10 | |
| US62/570,326 | 2017-10-10 | ||
| US201862727734P | 2018-09-06 | 2018-09-06 | |
| US62/727,734 | 2018-09-06 | ||
| PCT/IB2018/057735 WO2019073347A1 (en) | 2017-10-10 | 2018-10-04 | CRYSTALLINE BASE FREE HYDRATE SHAPE OF LORLATINIB |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020536893A JP2020536893A (ja) | 2020-12-17 |
| JP2020536893A5 true JP2020536893A5 (enExample) | 2021-05-27 |
| JP7153069B2 JP7153069B2 (ja) | 2022-10-13 |
Family
ID=64049474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520115A Active JP7153069B2 (ja) | 2017-10-10 | 2018-10-04 | ロルラチニブ遊離塩基水和物の結晶形態 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11299500B2 (enExample) |
| EP (1) | EP3694863B1 (enExample) |
| JP (1) | JP7153069B2 (enExample) |
| KR (1) | KR102424621B1 (enExample) |
| CN (1) | CN111201235B (enExample) |
| AU (1) | AU2018349259B2 (enExample) |
| CA (1) | CA3077508C (enExample) |
| CY (1) | CY1126141T1 (enExample) |
| DK (1) | DK3694863T3 (enExample) |
| ES (1) | ES2952985T3 (enExample) |
| FI (1) | FI3694863T3 (enExample) |
| HU (1) | HUE062926T2 (enExample) |
| MX (1) | MX2020003373A (enExample) |
| PL (1) | PL3694863T3 (enExample) |
| PT (1) | PT3694863T (enExample) |
| RU (1) | RU2022109286A (enExample) |
| SG (1) | SG11202002445SA (enExample) |
| SI (1) | SI3694863T1 (enExample) |
| TW (1) | TWI775960B (enExample) |
| WO (1) | WO2019073347A1 (enExample) |
| ZA (1) | ZA202001661B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1252845A1 (zh) | 2015-07-31 | 2019-06-06 | Pfizer Inc. | 劳拉替尼游离碱的结晶形式 |
| CA3019905C (en) | 2016-04-08 | 2022-08-23 | Pfizer Inc. | Crystalline forms of lorlatinib maleate |
| US20210163498A1 (en) * | 2018-04-23 | 2021-06-03 | Pliva Hrvatska D.O.O. | Solid state forms of lorlatinib and their preparation |
| WO2021011345A1 (en) * | 2019-07-18 | 2021-01-21 | Pliva Hrvatska D.O.O | Crystalline lorlatinib : fumaric acid and solid state form thereof |
| CN112321604A (zh) * | 2019-08-05 | 2021-02-05 | 华东理工大学 | 大环类jak2抑制剂及其应用 |
| WO2021069571A1 (en) | 2019-10-10 | 2021-04-15 | Sandoz Ag | Polymorph of lorlatinib |
| CN112824417A (zh) * | 2019-11-21 | 2021-05-21 | 上海天慈国际药业有限公司 | 一种劳拉替尼的制备方法 |
| WO2021176349A1 (en) | 2020-03-05 | 2021-09-10 | Pfizer Inc. | Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor |
| CN111362967B (zh) * | 2020-04-28 | 2021-09-07 | 南京雷正医药科技有限公司 | 苯并氧杂二氮杂十四碳烯衍生物及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2566858A2 (en) | 2010-05-04 | 2013-03-13 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
| EA024026B1 (ru) | 2010-11-25 | 2016-08-31 | Рациофарм Гмбх | Новые соли и полиморфные формы афатиниба |
| NZ618178A (en) * | 2011-06-08 | 2016-03-31 | Biogen Ma Inc | Process for preparing high purity and crystalline dimethyl fumarate |
| LT2822953T (lt) | 2012-03-06 | 2017-04-10 | Pfizer Inc. | Makrocikliniai dariniai, skirti proliferacinių ligų gydymui |
| US9637500B2 (en) * | 2013-06-28 | 2017-05-02 | Pfizer Inc. | Solid forms of a macrocyclic kinase inhibitor |
| CN107207528B (zh) * | 2014-08-20 | 2019-06-21 | 苏州韬略生物科技有限公司 | 作为激酶抑制剂的经取代大环及其使用方法 |
| WO2016026423A1 (en) * | 2014-08-20 | 2016-02-25 | Teligene Ltd | Substituted macrocycles useful as kinases inhibitors and methods of use thereof |
| HK1252845A1 (zh) * | 2015-07-31 | 2019-06-06 | Pfizer Inc. | 劳拉替尼游离碱的结晶形式 |
| CA3019905C (en) | 2016-04-08 | 2022-08-23 | Pfizer Inc. | Crystalline forms of lorlatinib maleate |
-
2018
- 2018-10-04 DK DK18795807.9T patent/DK3694863T3/da active
- 2018-10-04 RU RU2022109286A patent/RU2022109286A/ru unknown
- 2018-10-04 MX MX2020003373A patent/MX2020003373A/es unknown
- 2018-10-04 FI FIEP18795807.9T patent/FI3694863T3/fi active
- 2018-10-04 WO PCT/IB2018/057735 patent/WO2019073347A1/en not_active Ceased
- 2018-10-04 JP JP2020520115A patent/JP7153069B2/ja active Active
- 2018-10-04 US US16/650,505 patent/US11299500B2/en active Active
- 2018-10-04 AU AU2018349259A patent/AU2018349259B2/en active Active
- 2018-10-04 SI SI201830952T patent/SI3694863T1/sl unknown
- 2018-10-04 SG SG11202002445SA patent/SG11202002445SA/en unknown
- 2018-10-04 CA CA3077508A patent/CA3077508C/en active Active
- 2018-10-04 PT PT187958079T patent/PT3694863T/pt unknown
- 2018-10-04 HU HUE18795807A patent/HUE062926T2/hu unknown
- 2018-10-04 PL PL18795807.9T patent/PL3694863T3/pl unknown
- 2018-10-04 CN CN201880065709.6A patent/CN111201235B/zh active Active
- 2018-10-04 ES ES18795807T patent/ES2952985T3/es active Active
- 2018-10-04 EP EP18795807.9A patent/EP3694863B1/en active Active
- 2018-10-04 KR KR1020207010512A patent/KR102424621B1/ko active Active
- 2018-10-05 TW TW107135186A patent/TWI775960B/zh active
-
2020
- 2020-03-17 ZA ZA2020/01661A patent/ZA202001661B/en unknown
-
2023
- 2023-07-25 CY CY20231100357T patent/CY1126141T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536893A5 (enExample) | ||
| RU2022109286A (ru) | Кристаллическая форма гидрата свободного основания лорлатиниба | |
| JP2017039702A5 (enExample) | ||
| EP2678336B1 (en) | Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors | |
| RU2619944C2 (ru) | Твердые формы селективного ингибитора CDK4/6 | |
| AU2014298051B2 (en) | Novel quinazolinones as bromodomain inhibitors | |
| TWI643858B (zh) | 結晶型（８Ｓ，９Ｒ）－５－氟－８－（４－氟苯基）－９－（１－甲基－１Ｈ－１，２，４－三唑－５－基）－８，９－二氫－２Ｈ－吡啶并［４，３，２－ｄｅ］呔－３（７Ｈ）－酮甲苯磺酸鹽 | |
| JP2022058395A5 (enExample) | ||
| JP2020511467A5 (enExample) | ||
| JP2007521340A5 (enExample) | ||
| JP2014518266A5 (enExample) | ||
| CA2688708A1 (en) | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione | |
| HRP20231533T1 (hr) | Kristalni oblici od (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-il)pirolo[2,1-f][1,2,4 ]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amina i postupci priprave | |
| AU2013261128A1 (en) | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
| PH12014502531B1 (en) | Benzamine derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
| JP2016503010A5 (enExample) | ||
| JP2010514806A5 (enExample) | ||
| TW202128699A (zh) | 治療性化合物 | |
| JP2015500331A5 (enExample) | ||
| JP2015522037A5 (enExample) | ||
| JP2009534373A5 (enExample) | ||
| CN116406355A (zh) | P38α促分裂原活化蛋白激酶抑制剂 | |
| RU2018103172A (ru) | Кристаллическая фумаратная соль (s)-[3,4-дифтор-2-(2-фтор-4-йодфениламино)фенил][3-гидрокси-3-(пиперидин-2-ил)азетидин-1-ил]метанона | |
| CN103619354A (zh) | 止痒剂 | |
| JP2011528030A5 (enExample) |